SaRS-Cov-2 Antibodies Following Exposure to Coronavirus Disease 2019 (COVID-19) and/or Vaccination in Nursing Homes
1 other identifier
observational
1,293
1 country
1
Brief Summary
Presence of SaRS-Cov-2 antibodies following exposure to Coronavirus Disease 2019 (COVID-19) and/or vaccination is a major indicator of immunization. Few data exit about serology response in nursing homes (NHs), i.e. in the most vulnerable population for developing severe forms of the disease. Residents and health professionals in 9 nursing homes (NHs) with SaRS-Cov-2 antibodies detection after exposure (either COVID-19 or vaccine) All biological tests were performed in the frame of the standard care of residents and health professionals and all participants did not express opposition for using anonymously their data for the purpose of this academic analysis. In addition all Directors and Physicians of these NHs accepted to participate in this study
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 26, 2021
CompletedFirst Posted
Study publicly available on registry
July 15, 2021
CompletedStudy Start
First participant enrolled
July 15, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 15, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
May 15, 2022
CompletedJuly 19, 2022
July 1, 2022
10 months
June 26, 2021
July 18, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Levels of SARS-COV-2 antibodies
Study of the SARS-COV-2 antibodies according to the history of COVID-19 and vaccinal status in Nursing Home residents and in health professionals
Through study completion average 6 months Retrospective analysis
Study Arms (2)
Residents in Nursing homes
Health professionals in Nursing homes
Interventions
Analysis of the results of the serological response to COVID-19 and/or Vaccine
Eligibility Criteria
Residents of the 9 Nursing Homes that participate in this study Health professionals working these Nursing Homes
You may qualify if:
- For Residents:
- Living in one of the 9 Nursing Homes that participate in this study
- Having a SARS-COV-2 post vaccination serology.
- Having no objection for using the results of the serology for the purpose of this analysis
- For Health Professionals:
- Working in one of the 9 Nursing Homes that participate in this study,
- Having a SARS-COV-2 post vaccination serology.
- Having no objection for using the results of the serology for the purpose of this analysis
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHRU de Nancy, Université de Lorraine
Vandœuvre-lès-Nancy, US and Canada Only, 54500, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Athanase Benetos, Clinical Professor, Head of the Dpt of Geriatrics
Study Record Dates
First Submitted
June 26, 2021
First Posted
July 15, 2021
Study Start
July 15, 2021
Primary Completion
May 15, 2022
Study Completion
May 15, 2022
Last Updated
July 19, 2022
Record last verified: 2022-07